Vaginal misoprostol for cervical priming before operative hysteroscopy: a randomized controlled trial
Objective: To investigate the effectiveness of vaginal misoprostol for cervical priming before operative hysteroscopy and to assess the cervicouterine complications related to cervical dilatation and hysteroscopic surgery in nulliparous women. Methods: One hundred fifty-two women with definite intra...
Saved in:
Published in | Obstetrics and gynecology (New York. 1953) Vol. 96; no. 6; pp. 890 - 894 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.12.2000
The American College of Obstetricians and Gynecologists Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective: To investigate the effectiveness of vaginal misoprostol for cervical priming before operative hysteroscopy and to assess the cervicouterine complications related to cervical dilatation and hysteroscopic surgery in nulliparous women.
Methods: One hundred fifty-two women with definite intrauterine lesions were randomly assigned to receive either 200 μg vaginal misoprostol or placebo. Cervical response and outcome and complications of operative hysteroscopy were assessed.
Results: Thirty-five subjects were needed in each arm to detect a type I error of 0.01 with a power of 0.99. The mean cervical dilatation estimated by Hegar dilator was significantly different between the treated group (7.3 ± 0.7 mm) and the control group (3.8 ± 1.1 mm,
P < .001). In the misoprostol group, 55 (75.3%) patients needed cervical dilation, compared with 75 (94.9%,
P = .001) in the placebo group. The median time of cervical dilation to Hegar number 9 was significantly shorter in the treated group (40 seconds) compared with the control group (120 seconds,
P < .001). The mean operative time was significantly shorter in the treated group (36.4 ± 10.9 minutes) compared with the control group (45.9 ± 14.2 minutes,
P < .001). Cervical tears occurred in nine (11.4%) patients in the control group and in one (1.4%,
P = .018) in the misoprostol group. Creation of a false tract was more common in the control group. Two uterine perforations occurred in the placebo group.
Conclusion: Vaginal misoprostol applied before operative hysteroscopy reduced the need for cervical dilation, facilitated hysteroscopic surgery, and minimized cervical complications. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
ISSN: | 0029-7844 1873-233X |
DOI: | 10.1016/S0029-7844(00)01063-2 |